Patents by Inventor Alphonse P. Granatek

Alphonse P. Granatek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4451447
    Abstract: Stable concentrated solutions of cisplatin in a solvent comprising polyethylene glycol or methoxy polyethylene glycol, or a mixture thereof, plus water and a nontoxic pharmaceutically acceptable source of chloride ion.
    Type: Grant
    Filed: December 24, 1981
    Date of Patent: May 29, 1984
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, Alphonse P. Granatek
  • Patent number: 4335244
    Abstract: This invention concerns three particular crystalline monolactate salts of the antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide. The salts are characterized in having unexpectedly high water-solubility.
    Type: Grant
    Filed: May 23, 1980
    Date of Patent: June 15, 1982
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, Alphonse P. Granatek
  • Patent number: 4322362
    Abstract: Disclosed are water-soluble salts of the known coordination compounds 2-hydroxymalonato diammine platinum (II), 2-hydroxymalonato (1,2-diaminocyclohexane)platinum (II) and 2-hydroxymalonato (1,1-diaminomethylcyclohexane)platinum (II). The novel sodium and ammonium salts of the present invention possess high water-solubility, thus allowing intravenous dosage forms to be prepared.
    Type: Grant
    Filed: January 22, 1981
    Date of Patent: March 30, 1982
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, Alphonse P. Granatek
  • Patent number: 4322391
    Abstract: A stable, microcrystalline form of cisplatin, a process for its preparation, and stable, sterile dry-mix formulations thereof which are more rapidly reconstituted with sterile water to produce solutions suitable for intravenous administration to man than are similar formulations containing "regular" cisplatin. The microcrystalline cisplatin and dry-mix formulations thereof are prepared without the use of lyophilization.
    Type: Grant
    Filed: September 29, 1980
    Date of Patent: March 30, 1982
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, Alphonse P. Granatek
  • Patent number: 4302446
    Abstract: A stable, microcrystalline form of cisplatin, a process for its preparation, and stable, sterile dry-mix formulations thereof which are more rapidly reconstituted with sterile water to produce solutions suitable for intravenous administration to man than are similar formulations containing "regular" cisplatin. The microcrystalline cisplatin and dry-mix formulations thereof are prepared without the use of lyophilization.
    Type: Grant
    Filed: October 2, 1979
    Date of Patent: November 24, 1981
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, Alphonse P. Granatek
  • Patent number: 4297489
    Abstract: Certain 7-acylamido-3-(1-carboxy-loweralkyl-tetrazol-5-ylthiomethyl)-3-cephem-4-ca rboxylic acids and their salts and easily hydrolyzed esters of the 4-carboxyl group were synthesized and found to be potent antibacterial agents which exhibited good aqueous solubility. In a preferred embodiment the 7-substituent was 2'-aminomethylphenylacetamido.
    Type: Grant
    Filed: June 27, 1975
    Date of Patent: October 27, 1981
    Assignee: Bristol-Myers Company
    Inventors: William J. Gottstein, Murray A. Kaplan, Alphonse P. Granatek
  • Patent number: 4182863
    Abstract: Certain 7-acylamido-3-(1-carboxymethyltetrazol-5-ylthiomethyl)-3-cephem-4-carboxyl ic acids and their salts and easily hydrolyzed esters of the 4-carboxyl group were synthesized and found to be potent antibacterial agents which exhibited good aqueous solubility. In a preferred embodiment the 7-substituent was 2'-aminomethylphenylacetamido.
    Type: Grant
    Filed: August 5, 1976
    Date of Patent: January 8, 1980
    Assignee: Bristol-Myers Company
    Inventors: William J. Gottstein, Murray A. Kaplan, Alphonse P. Granatek
  • Patent number: 4180658
    Abstract: Cephalosporins in a series having the formula ##STR1## wherein R.sup.1 is alkyl containing 1-4 carbon atoms or a nontoxic pharmaceutically acceptable salt thereof, were synthesized and found to be potent antibacterial agents especially when in the form of the syn isomers essentially free of the corresponding anti isomer.
    Type: Grant
    Filed: February 24, 1978
    Date of Patent: December 25, 1979
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, Alphonse P. Granatek, Solomon J. Nachfolger
  • Patent number: 4172196
    Abstract: Certain 7-acylamido-3-(1-carboxymethyltetrazol-5-yl-thiomethyl)-3-cephem-4-carboxy lic acids and their salts and easily hydrolyzed esters of the 4-carboxyl group were synthesized and found to be potent anti-bacterial agents which exhibited good aqueous solubilty. In a preferred embodiment the 7-substituent was D-.alpha.-hydroxyphenylcetamido.
    Type: Grant
    Filed: July 28, 1976
    Date of Patent: October 23, 1979
    Assignee: Bristol-Myers Company
    Inventors: William J. Gottstein, Murray A. Kaplan, Alphonse P. Granatek
  • Patent number: 4161595
    Abstract: The invention concerns a levulinic acid addition salt of the antihypertensive agent 4-amino-6,7-dimethoxy-2-[4-(5-methylthio-1,3,4-oxadiazole-2-carbonyl]piper azin-1-yl)quinazoline in which the base to acid mole ratio is 1 to from 1.25-1.35. The salt is characterized in having improved water solubility and stability compared to the levulinate salt having a 1:1 ratio of base to acid.
    Type: Grant
    Filed: October 2, 1978
    Date of Patent: July 17, 1979
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, Alphonse P. Granatek
  • Patent number: 4100346
    Abstract: Certain 7-acylamido-3-[1-carboxymethyl-(or ethyl- or propyl-)-tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acids and their salts and easily hydrolyzed esters of the 4-carboxyl group were synthesized and found to be potent antibacterial agents which exhibited good aqueous solubility. A preferred embodiment was 7-(2-aminomethylphenylacetamido)-3-(1-carboxymethyltetrazol-5-ylthiomethyl )-3-cephem-4-carboxylic acid.
    Type: Grant
    Filed: June 11, 1976
    Date of Patent: July 11, 1978
    Assignee: Bristol-Myers Company
    Inventors: William J. Gottstein, Murray A. Kaplan, Alphonse P. Granatek
  • Patent number: 4091213
    Abstract: Compounds of the formula ##STR1## wherein A is hydrogen, hydroxy, methyl or methoxy,R.sup.1 is hydrogen, sodium or potassium,R.sup.2 is carboxyl or 2-furyl or an aliphatic, aromatic or heterocyclic radical to which there is also attached a strongly acidic group in the form of its sodium or potassium salt, andR.sup.3 is tetrazol-5-yl, 1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-2-yl, 1,3,4-oxadiazol-3-yl or 1,2,4-triazol-5-yl, each of such groups being unsubstituted or substituted with one or two lower alkyl groups of one to four carbon atoms are prepared by reacting the appropriate aldehyde with the corresponding amphoteric cephalosporin. Preferred products have the structure ##STR2## in which A is --H or --SO.sub.3 Na.
    Type: Grant
    Filed: January 10, 1977
    Date of Patent: May 23, 1978
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, William J. Gottstein, Alphonse P. Granatek
  • Patent number: 4064345
    Abstract: Compounds of the formula ##STR1## wherein A is hydrogen, hydroxy, methyl or methoxy,R.sup.1 is hydrogen, sodium or potassium,R.sup.2 is carboxyl or 2-furyl or an aliphatic, aromatic or heterocyclic radical to which there is also attached a strongly acidic group in the form of its sodium or potassium salt, andR.sup.3 is tetrazol-5-yl, 1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-2-yl, 1,3,4-oxadiazol-3-yl or 1,2,4-triazol-5-yl, each of such groups being unsubstituted or substituted with one or two lower alkyl groups of one to four carbon atoms are prepared by reacting the appropriate aldehyde with the corresponding amphoteric cephalosporin. Preferred products have the structure ##STR2## in which A is --H or --SO.sub.3 Na.
    Type: Grant
    Filed: November 26, 1976
    Date of Patent: December 20, 1977
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, William J. Gottstein, Alphonse P. Granatek
  • Patent number: 4061862
    Abstract: Compounds of the formula ##STR1## wherein A is hydrogen, hydroxy, methyl or methoxy,R.sup.1 is hydrogen, sodium or potassium, andR.sup.2 is 1,2,3-triazol-5-yl, such group being unsubstituted or substituted with one or two lower alkyl groups of one to four carbon atoms are prepared by reacting the appropriate aldehyde with the corresponding amphoteric cephalosporin.
    Type: Grant
    Filed: February 2, 1976
    Date of Patent: December 6, 1977
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, William J. Gottstein, Alphonse P. Granatek
  • Patent number: 4035381
    Abstract: The alkali metal salts of the reaction products of ampicillin or amoxicillin with 5-formyl-2-furansulfonic acid are found to be stable, useful water-soluble forms of the penicillin antibiotics especially advantageous for parenteral administration.
    Type: Grant
    Filed: October 26, 1976
    Date of Patent: July 12, 1977
    Assignee: Bristol-Myers Company
    Inventors: Murray Arthur Kaplan, William Joseph Gottstein, Alphonse P. Granatek
  • Patent number: 4026888
    Abstract: Compounds of the formula ##STR1## wherein A is hydrogen, hydroxy, methyl or methoxy,R.sup.1 is hydrogen, sodium or potassium,R.sup.2 is carboxyl or an aliphatic, aromatic or heterocyclic radical to which there is also attached a strongly acidic group in the form of its sodium or potassium salt, andR.sup.3 is 1,2,3-triazol-5-yl, such group being unsubstituted or substituted with one or two lower alkyl groups of one to four carbon atoms are prepared by reacting the appropriate aldehyde with the corresponding amphoteric cephalosporin.
    Type: Grant
    Filed: January 30, 1976
    Date of Patent: May 31, 1977
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, William J. Gottstein, Alphonse P. Granatek